glp 1 medication canada greenlights first daily GLP-1 pill for heart and diabetes 3 million Canadians use GLP-1

Earnings per share came in at $2.14, exceeding an LSEG forecast of $1.93 per share

Initial assessment Clinical monitoring Comprehensive treatment For patients with type 2 diabetes GLP-1 treatment has been shown to: The entire process is carried out under continuous medical supervision, focusing on glycemic control and sustainable fat reduction

Cagrilintide is designed as a long-acting analogue for once-weekly dosing

It is not recommended for children under 15 years of age, pregnant or lactating women, or caffeine sensitive individuals

1 It binds to skin cell receptors to enhance gene expression related to repair and renewal, reducing the activity of enzymes that degrade skin structural proteins with age, and helping restore the skins natural regeneration processes